论文部分内容阅读
本文采用6及9个月HRE短化方案与3SHP/15HP标化方案进行近、远期疗效的对照研究。前次报告已验证两个短化方案与标化方案的近期疗效极为相似。满疗程的481例进行随访观察,5年中失访56例。复发15例,其中12例在停药后1年半内复发。6及9个月短化方案的细菌学及X线总复发率分别为5.8％和1.1％,与标化组(3.9％)比较无显著性差异(P>0.05);但6HRE组复发高于9HRE组P<0.05)。三组随访5年X线继续进步率分别为36.9％、39.5％及41.9％,无显著性差异(P>0.05)。本结果证实含RFP而无PZA的方案,9个月疗程是可行的。并提示短化科研随访时间可减至3年。
In this paper, 6 and 9 months of HRE short program and 3SHP / 15HP standardization program for short-term and long-term efficacy of the controlled study. The previous report has verified that the short-term outcomes of the two short-term and standardized regimens are very similar. 481 cases of full course of treatment were followed up, 56 cases were lost in 5 years. Recurrent in 15 cases, of which 12 cases relapsed within 1 year and a half after stopping. The total bacteriological and X-ray recurrence rates at 6 and 9 months were 5.8% and 1.1%, respectively, with no significant difference from the standard group (3.9%) (P> 0.05) 9HRE group P <0.05). The follow-up 5-year follow-up X-ray continued to improve rates were 36.9%, 39.5% and 41.9%, no significant difference (P> 0.05). This result confirms a regimen of RFP without PZA, with a 9-month course of treatment feasible. And prompts to shorten the duration of scientific research can be reduced to 3 years.